Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer

Authors

Qi Yingwei, Greater Baltimore Medical Center (GBMC)

Document Type

Article

Publication Title

Anti-Cancer Drugs

First Page

1079

Last Page

1083

DOI

https://doi.org/10.1097/cad.0000000000000009

Publication Date

11-2013

Recommended Citation

Mansfield AS, Fields AP, Jatoi A, Qi Y, Adjei AA, Erlichman C, Molina JR. Phase I dose escalation study of the PKCι inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. Anticancer Drugs. 2013 Nov;24(10):1079-83. doi: 10.1097/CAD.0000000000000009. PMID: 23962904; PMCID: PMC3937851.